Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Case Study #1: Replidyne’s Faropenem Program Caught In The Crossfire

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Louisville, Colo.-based Replidyne is particularly invested in the recent FDA draft guidances concerning the use of non-inferiority trial designs in anti-infective studies: the NDA submission for their lead candidate, faropenem medoxomil, is caught in the midst of evolving standards for anti-infective approvals.

You may also be interested in...



Industry Diagnoses Need For R&D Incentives, Cites Regulatory Track Infection

Without clear guidance from FDA on what it is looking for in anti-infective drug development, there isn't enough incentive for sponsors to continue R&D in the area, industry reps cautioned at the CAP public workshop.

Case Study #2: Why Waiting Is Better For Advanced Life Sciences

While companies like Replidyne and Sanofi-Aventis have been caught in the evolving regulatory standards for non-inferiority trial design in antibiotics, one firm has elected to wait for further clarification before submitting a new drug application.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

PS003758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel